Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, CEO & Director | 940.7k | -- | 1967 |
| Ms. Jennifer Ziolkowski CPA | Chief Financial Officer | 650.89k | -- | 1975 |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer | 665.9k | -- | 1966 |
| Ms. Sharon Morani | Senior Director of Facilities & Operations | -- | -- | -- |
| Dr. David Gray Ph.D. | Chief Scientific Officer | 601.57k | -- | 1975 |
| Eric Brophy | Senior Manager of Information Technology | -- | -- | -- |
| Ms. Leah Gibson | Vice President of Investor Relations and Corporate Communications | -- | -- | -- |
| Ms. April Effort M.B.A., M.S. | VP & Head of Corporate Development | -- | -- | -- |
| Mr. Evan A. Thackaberry DABT, Ph.D. | Senior VP & Head of Early Development | -- | -- | 1973 |
| Christian Mirescu Ph.D. | Senior VP & Head of Neuroimmunology | -- | -- | -- |
Vigil Neuroscience, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 69
Description
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available